Building the next generation of healthcare companies

Freeline Presents Data Highlighting Platform Technology at the American Society of Gene and Cell Therapy Annual Meeting 2021

Download a copy of our latest presentation (1.40Mb)

Who we are

Syncona, found, builds and funds companies in innovative areas of healthcare, targeting the superior risk-adjusted returns available from commercialising exceptional science.

Investors

Syncona is a FTSE250 business listed on the London Stock Exchange. Find the latest share price, announcements, presentations and events here.

An Introduction to Gene Therapy

Syncona’s Chief Investment Officer, Chris Hollowood and Syncona Partner, Dominic Schmidt, provide an introduction to gene therapy, a field where Syncona has developed deep domain expertise and built a strategic platform.

Found, Build and Fund

Syncona’s Chief Executive, Martin Murphy and Syncona Partner, Elisa Petris describe Syncona’s strategy to Found, Build and Fund global leaders in life science.